ArticleFrontiers in microbiology2025
Development of a nucleocapsid protein-based competitive ELISA for the detection of porcine deltacoronavirus antibodies.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid On-Site Detection ofPlants (Basel, Switzerland) · 2026Article
- Identification of a novel N-terminal linear B-cell epitope on the FIPV nucleocapsid protein by a monoclonal antibody.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine deltacoronavirus (PDCoV) is a significant threat to the global swine industry, causing severe diarrhea in piglets and exhibiting a broad host range with zoonotic potential. The nucleocapsid (N) protein of PDCoV is highly conserved and immunogenic, making it an ideal target for diagnostic development. However, existing enzyme-linked immunosorbent assays (ELISAs) typically rely on enzyme-labeled secondary antibodies, complicating the experimental procedure. In this study, a monoclonal antibody (mAb 3C6) against the PDCoV N protein was developed and utilized to establish a competitive ELISA (cELISA). The recombinant N protein (~40 kDa) was successfully expressed and purified. Epitope mapping identified the linear B-cell epitope recognized by mAb 3C6 as 121-HQLLPLRFPTGDGPA-135. Using 60 PDCoV-negative serum samples, the cut-off value for the cELISA was determined to be 44.3%. Validation with 175 field swine serum samples demonstrated a diagnostic sensitivity of 88.5%, specificity of 92.6%, and an overall agreement of 92.0%. The cELISA showed analytical sensitivity twice that of an indirect immunofluorescence assay (IFA) and detected PDCoV-specific antibodies as early as 7 days post-infection. No cross-reactivity with other common swine pathogens was observed. The coefficients of variation for intra- and inter-assay reproducibility ranged from 4.39 to 9.20% and 4.20 to 7.97%, respectively. In conclusion, the developed N protein-based cELISA represents a reliable and efficient tool for the serological detection of PDCoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.